Skip to main content

Model-informed precision dosing of busulfan in Adults: Real world implications for Dosing and Transplant outcomes

Journal
Transplantation and cellular therapy (Q1)
Published
14 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Bracha L, Aldouby-Bir G, Katz A, Elias S, Zimran E, Shaulov A, et al.
PMID
43025811
DOI
10.1016/j.jtct.2026.10.042

Why clinicians should know about it

  • Picked for Hematology (paper of the day, 18 November 2026): Assesses busulfan precision dosing and allogeneic transplant outcomes

Abstract

BACKGROUND: Busulfan has been a cornerstone of conditioning regimens for hematopoietic cell transplantation (HCT) for decades. Systemic busulfan exposure has been associated with clinical outcomes. Both underexposure and overexposure carry risks of relapse and graft failure on one hand, and toxicity or non-relapse mortality on the other. Model-informed precision dosing (MIPD), based on early pharmacokinetic measurements, has been introduced to optimize individual exposure and improve outcomes. OBJECTIVE: This study aims to evaluate the impact of MIPD on transplantation outcomes in adults treated at a large medical center. STUDY DESIGN: This retrospective cohort study included adult patients who underwent allogeneic HCT for malignant diseases between 1/1/2010 and 31/12/2022. Patients were divided into two groups based on the intravenous busulfan dosing strategy, a body weight-based dosing group (1/1/2010 to 31/12/2017) and a MIPD group (31/12/2017 to 31/12/2022). Busulfan plasma concentrations were measured after the first dose and analyzed using the NextDose platform to guide individualized dosing. The cumulative target AUC over 4 days was 79 mgh/L. Transplantation and disease related variables, toxicity (CTCAE grade 3-4 by day 100), and graft-versus-host disease (GVHD) were recorded. Survival outcomes included overall survival (OS), event-free survival (EFS), GVHD-free relapse-free survival (GRFS), relapse-free survival (RFS), and non-relapse mortality (NRM). Multivariable logistic regression, Cox proportional hazards models, and competing risk analyses using Fine-Gray models were applied. RESULTS: Among 107 patients, 62 received weight-based busulfan and 45 received MIPD. Baseline characteristics were largely comparable, although the MIPD group had a different ethnic distribution (p=0.007) and a lower Karnofsky score (p=0.024). Survival outcomes favored the MIPD group with OS (p=0.004), EFS (p=0.0053) and GRFS (p=0.0047). Higher conditioning intensity (dual alkylating agents) was associated with lower relapse in both groups (p=0.040, 0.011) and with improved OS only in the weight-based dosing group (p<0.001). Mucositis was more frequent with MIPD (p<0.001), and GVHD rates were similar between groups. In multivariable Cox regression analysis, MIPD (HR 0.40; p=0.009) and conditioning intensity (HR 0.37; p=0.003) were independently associated with improved OS. Competing risk analysis showed significantly lower non-relapse mortality in the MIPD group (p=0.009), but no significant difference in relapse probability (p=0.44). CONCLUSIONS: Our study compared weight-based dosing and MIPD of busulfan in adults undergoing allogeneic HCT. Transplantation outcomes were improved due to reduced mortality in the busulfan MIPD cohort. These finding highlight the potential of individualized dosing strategies to improve the therapeutic balance in transplantation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.